Roche Receives FDA 510(k) Clearance for cobas® BV/CV Assay, Bringing PCR Precision to Vaginitis Diagnosis
核心洞察
Roche announced FDA 510(k) clearance for its cobas® BV/CV molecular assay, enabling simultaneous PCR-based detection of Bacterial vaginosis (搜索) and Candida vaginitis (搜索) from a single vaginal swab.
The assay addresses a critical diagnostic gap, as traditional methods like microscopy and pH testing result in misdiagnosis rates approaching 50%, raising the risk of recurrence.
Bacterial vaginosis (搜索) affects approximately 27% of reproductive-age women in North America, while up to 75% of women experience Candida vaginitis (搜索) at least once in their lifetime.
Roche announced on July 24, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis (搜索)/Candida vaginitis (搜索)) assay, a molecular diagnostic test that simultaneously detects organisms associated with the two most common causes of vaginitis from a single vaginal swab sample. The clearance marks a significant advancement in women's health diagnostics, addressing longstanding challenges in accurately diagnosing these prevalent conditions.
"Compared to traditional methods, the cobas® BV/CV test can help improve diagnostic accuracy for women affected by vaginitis, addressing a critical need in women's health," said Brad Moore, President and CEO, Roche Diagnostics North America. "By expanding our sexual-health portfolio to include comprehensive results for the most common conditions from a single sample, we can streamline care to help patients receive the right treatment faster."
The Diagnostic Challenge in Vaginitis
Vaginitis ranks among the most common reasons women seek medical care, with Bacterial vaginosis (搜索) (BV) and Candida vaginitis (搜索) (CV) representing two of the most frequent infectious causes. Clinicians have traditionally depended on microscopy, pH testing, and clinical observation to diagnose these conditions, yet these methods lack precision. According to the source materials, misdiagnosis of vaginitis approaches 50%, significantly elevating the risk of recurrence.
The disease burden is substantial: BV impacts approximately 27% of women of reproductive age in North America, while up to 75% of women experience CV at least once in their lifetime. Symptoms — including itching, burning, discharge, and irritation — are often non-specific, complicating accurate clinical assessment. Furthermore, BV and CV infections are associated with an increased risk of sexually transmitted infections.
Molecular Technology and Target Detection
The cobas® BV/CV assay employs real-time polymerase chain reaction (PCR) technology to identify specific bacterial and yeast DNA targets in vaginal samples from symptomatic patients. For BV, the test detects Gardnerella vaginalis (搜索), Atopobium vaginae (搜索), and Lactobacillus spp. For CV, it identifies a broad panel of Candida species: C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and C. dubliniensis.
The assay aligns with Centers for Disease Control and Prevention guidelines, which do not recommend speciation prior to first-line therapy. Additional Candida speciation or susceptibility testing is advised only in cases of persistent or recurrent infection — defined as three or more episodes of symptomatic CV within one year — or documented treatment failure with first-line therapy.
Sample Collection and Portfolio Integration
Sample collection utilizes clinician-collected or clinician-instructed, self-collected vaginal swabs in cobas® PCR Media within a healthcare setting. A key advantage of the system is that a single sample can also be used for broader sexual-health testing with Roche's cobas® CT/NG (Chlamydia trachomatis/Neisseria gonorrhoeae) and cobas® TV/MG (Trichomonas vaginalis/Mycoplasma genitalium) assays, eliminating the need for additional specimen collection.
The assay expands the testing menu on the cobas® 6800/8800 systems, enabling laboratories, hospitals, and sexual-health clinics to deliver faster, more efficient workflows. Roche also plans to add the cobas® 5800 system to the assay through the FDA's Reagent Replacement and Instrument Family Policy. The commercial launch is expected later this year.
The cobas® BV/CV assay is available for professional laboratory use only, based on a clinician's order.